Impax Asset Management Group plc Acquires 19,894 Shares of Gilead Sciences, Inc. $GILD

robot
Abstract generation in progress

Impax Asset Management Group plc increased its stake in Gilead Sciences, Inc. by 7.2% in the fourth quarter, purchasing an additional 19,894 shares. Other institutional investors also adjusted their holdings. Insiders, including CEO Daniel Patrick O’day, sold shares, while Wall Street analysts largely maintain a “Moderate Buy” rating with an average target price of $157.35.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin